ROMATOİD ARTRİT TEDAVİSİNDE NANOTEKNOLOJİ DESTEKLİ İLAÇ VERİLİŞİ

Öz

Amaç: Romatoid artrit (RA), dünya nüfusunun yaklaşık %1’ini etkileyen kronik otoimmun bir hastalıktır. Kemik ve kıkırdakta bozulma, ağrı, vücudun birçok bölgesinde enflamasyonla karakterize bir hastalık olup ilerleyen süreçte ölümle de sonuçlanabilmektedir. Patogenezi tam olarak anlaşılamadığından tedavisi tam olarak yapılamamakta olup mevcut tedavide amaçlanan, geri dönüşümsüz eklem hasarını önlemek ve semptomatik rahatlama sağlayarak hastaların yaşam kalitesini artırmaktır. Standart tedaviler, hedefe spesifik olmamaları, uygulama sıklığı, doz artışı ve sistemik veya lokal yan etkileri, hastaların tolerans kazanması gibi nedenlerle yetersiz kalmaktadır. Bu derlemede romatoid artritin mevcut tedavilerindeki yetersizliklerin üstesinden gelebilmek için potansiyel nano boyutlu ilaç taşıyıcı sistemler ile ilgili bilgiler sunulmuştur.

Sonuç ve Tartışma: Nanoteknoloji, sağlık sektöründe hastalıkların tedavi edilmesinden erken teşhisine kadar birçok alanda kullanılmaktadır. Nanoteknolojik ilaç taşıyıcı sistemler, mümkün olduğunca hastalık bölgesine yönlendirilerek yan etkileri azaltmak ve daha etkin tedavi sağlamak için tasarlanmaktadır. Böylece geleneksel tedavinin dezavantajlarını ortadan kaldırarak, aktif ve pasif hedefleme stratejileriyle hedefe özgü, etkili ve güvenli yeni tedavi olanakları sunmaktadır.

Anahtar Kelimeler

• Akıllı ilaç salım sistemi
• nano taşıyıcı sistem
• nanoteknoloji
• romatoid artrit

NANOTECHNOLOGY-ASSISTED DRUG DELIVERY IN THE TREATMENT OF RHEUMATOID ARTHRITIS

Öz

Objective: Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects approximately 1% of the world's population. It is a disease characterized by bone and cartilage deterioration, pain, and inflammation in many parts of the body, and can even result in death in the future. Since its pathogenesis is not fully understood, it cannot be fully treated, and the aim of the current treatment is to prevent irreversible joint damage and to improve the quality of life of patients by providing symptomatic relief. Standard treatments are inadequate due to reasons such as not being target specific, frequency of application, increased doses, systemic or local side effects, and tolerance of patients to drugs. This review provides information on potential nano-sized drug delivery systems to overcome the shortcomings of current treatments for rheumatoid arthritis.

Result and Discussion: Nanotechnology is used in many areas in the health sector, from treating diseases to early diagnosis. Nanotechnological drug delivery systems are designed to reduce side effects and provide more effective treatments by directing them to the disease area as much as possible. Thus, by eliminating the disadvantages of traditional treatment, it offers new target-specific, effective and safe treatment opportunities with active and passive targeting strategies.

Anahtar Kelimeler

• Smart drug delivery system
• nano delivery system
• nanotechnology
• rheumatoid arthritis

Kaynakça

1. 1. Kumar, V., Kanwar, J.R., Verma, A.K. (2020). Chapter 16 - Rheumatoid Arthritis: Basic Pathophysiology and Role of Chitosan Nanoparticles in Therapy. Eds: Singh, M.R., Singh, D., Kanwar, J.R., Chauhan, N.S. Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents, Academic Press, New York, 481-507.
2. 2. Singh, S., Singh, S. (2020). JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis. International Immunopharmacology, 86, 106731. [CrossRef]
3. 3. Sezer, S., Turgay, T.M. (2020). Romatoid Artrit Epidemiyolojisi, Klinik Özellikleri ve Tanısı. Eds: Ateş, A. Romatoid Artrit-2020, Türkiye Klinikleri, Ankara, 8-13.
4. 4. Syed, A., Devi, V.K. (2019). Potential of targeted drug delivery systems in treatment of rheumatoid arthritis. Journal of Drug Delivery Science and Technology, 53, 101217. [CrossRef]
5. 5. Simon, L.S., Taylor, P.C., Choy, E.C., et al. (2021). The Jak/STAT pathway: A focus on pain in rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 51(1), 278-284. [CrossRef]
6. 6. Kolarz, B., Podgorska, D., Podgorski, R. (2021). Insights of rheumatoid arthritis biomarkers. Biomarkers, 26(3), 185-195. [CrossRef]
7. 7. Dougados, M. (2016). Comorbidities in rheumatoid arthritis. Current Opinion in Rheumatology, 28(3), 282-288. [CrossRef]
8. 8. Verma, A., Jain, A., Tiwari, A., et al. (2019). Folate conjugated double liposomes bearing prednisolone and methotrexate for targeting rheumatoid arthritis. Pharmaceutical Research, 36(8), 123. [CrossRef]

9. 9. Jeong, H., Baek, S.Y., Kim, S.W., et al. (2017). Comorbidities of rheumatoid arthritis: Results from the Korean national health and nutrition examination survey. Public Library of Science One, 12(4), e0176260. [CrossRef]
10. 10. Wang, Q., Qin, X., Fang, J., et al. (2021). Nanomedicines for the treatment of rheumatoid arthritis: State of art and potential therapeutic strategies. Acta Pharmaceutica Sinica B, 11(5), 1158-1174. [CrossRef]
11. 11. Qindeel, M., Ullah, M.H., Din, F.U., et al. (2020). Recent trends, challenges and future outlook of transdermal drug delivery systems for rheumatoid arthritis therapy. Journal of Controlled Release, 327, 595-615. [CrossRef]
12. 12. Catrina, A.I., Ytterberg, A. J., Reynisdottir, G., et al. (2014). Lungs, joints and immunity against citrullinated proteins in rheumatoid arthritis. Nature Reviews Rheumatology, 10(11), 645-653. [CrossRef]
13. 13. Shi, J., Knevel, R., Suwannalai, P., et al. (2011). Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proceedings of the National Academy of Sciences of the United States of America, 108(42), 17372-17377. [CrossRef]
14. 14. Petrovská, N., Prajzlerová, K., Vencovský, J., et al. (2021). The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis. Autoimmunity Reviews, 20(5), 102797. [CrossRef]
15. 15. van Drongelen, V., Holoshitz, J. (2017). Human leukocyte antigen-disease associations in rheumatoid arthritis. Rheumatic Disease Clinics of North America, 43(3), 363-376. [CrossRef]
16. 16. Corrigall, V.M., Panayi, G.S. (2002). Autoantigens and immune pathways in rheumatoid arthritis. Critical Reviews in Immunology, 22(4), 281-293. [CrossRef]
17. 17. Kurkó, J., Besenyei, T., Laki, J., et al. (2013). Genetics of rheumatoid arthritis - a comprehensive review. Clinical Reviews in Allergy & Immunology, 45(2), 170-179. [CrossRef]
18. 18. Carmona, F.D., Martín, J. (2018). The potential of PTPN22 as a therapeutic target for rheumatoid arthritis. Expert Opinion on Therapeutic Targets, 22(10), 879-891. [CrossRef]
19. 19. Begovich, A.B., Carlton, V.E.H, Honigberg, L.A., et al. (2004). A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. American Journal of Human Genetics, 75(2), 330-337.
20. 20. Márquez, A., Kerick, M., Zhernakova, A., et al. (2018). Meta-analysis of Immunochip data of four autoimmune diseases reveals novel single-disease and cross-phenotype associations. Genome Medicine, 10(1), 97. [CrossRef]
21. 21. Okada, Y., Eyre, S., Suzuki, A., et al. (2019). Genetics of rheumatoid arthritis: 2018 status. Annals of the Rheumatic Diseases, 78(4), 446-453. [CrossRef]
22. 22. Ham, S., Bae, J.B., Lee, S., et al. (2019). Epigenetic analysis in rheumatoid arthritis synoviocytes. Experimental & Molecular Medicine, 51(2), 1-13. [CrossRef]
23. 23. Trenkmann, M., Brock, M., Ospelt, C., et al. (2010). Epigenetics in rheumatoid arthritis. Clinical Reviews in Allergy & Immunology, 39(1), 10-19. [CrossRef]
24. 24. Alivernini, S., Gremese, E., McSharry, C., et al. (2017). MicroRNA-155-at the Critical Interface of Innate and Adaptive Immunity in Arthritis. Frontiers in Immunology, 8, 1932. [CrossRef]
25. 25. Su, L.C., Huang, A.F., Jia, H., et al. (2017). Role of microRNA-155 in rheumatoid arthritis. International Journal of Rheumatic Diseases, 20(11), 1631-1637. [CrossRef]
26. 26. Ouboussad, L., Hunt, L., Hensor, E.M.A., et al. (2017). Profiling microRNAs in individuals at risk of progression to rheumatoid arthritis. Arthritis Research & Therapy, 19(1), 288. [CrossRef]
27. 27. Mousavi, M.J., Jamshidi, A., Chopra, A., et al. (2018). Implications of the noncoding RNAs in rheumatoid arthritis pathogenesis. Journal of Cellular Physiology, 234(1), 335-347. [CrossRef]
28. 28. Khuder, S.A., Peshimam, A.Z., Agraharam, S. (2002). Environmental risk factors for rheumatoid arthritis. Reviews on Environmental Health, 17(4), 307-315. [CrossRef]
29. 29. Deane, K.D., Demoruelle, M.K., Kelmenson, L.B., et al. (2017). Genetic and environmental risk factors for rheumatoid arthritis. Best Practice & Research Clinical Rheumatology, 31(1), 3-18. [CrossRef]
30. 30. Maxwell, J.R., Gowers, I.R., Moore, D.J., et al. (2010). Alcohol consumption is inversely associated with risk and severity of rheumatoid arthritis. Rheumatology (Oxford), 49(11), 2140-2146. [CrossRef]
31. 31. Aletaha, D., Neogi, T., Silman, A.J., et al. (2010). Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatology, 62(9), 2569-2581. [CrossRef]
32. 32. Radner, H., Neogi, T., Smolen, J.S., et al. (2014). Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: A systematic literature review. Annals of the Rheumatic Diseases, 73(1), 114-123. [CrossRef]
33. 33. Kuchler-Bopp, S., Mariotte, A., Strub, M., et al. (2020). Temporomandibular joint damage in K/BxN arthritic mice. International Journal of Oral Science, 12(1), 5. [CrossRef]
34. 34. Sudoł-Szopińska, I., Jans, L., Teh, J. (2017). Rheumatoid arthritis: what do MRI and ultrasound show. Journal of Ultrasonography, 17(68), 5-16.
35. 35. Wenham, C.Y., Grainger, A.J., Conaghan, P.G. (2014). The role of imaging modalities in the diagnosis, differential diagnosis and clinical assessment of peripheral joint osteoarthritis. Osteoarthritis Cartilage, 22(10), 1692-1702. [CrossRef]
36. 36. Bhatnagar, S., Khera, E., Liao, J., et al. (2019). Oral and subcutaneous administration of a near-infrared fluorescent molecular imaging agent detects inflammation in a mouse model of rheumatoid Arthritis. Scientific Reports, 9(1), 4661. [CrossRef]
37. 37. Rahimizadeh, P., Rezaieyazdi, Z., Behzadi, F., et al. (2021). Nanotechnology as a promising platform for rheumatoid arthritis management: Diagnosis, treatment, and treatment monitoring. International Journal of Pharmaceutics, 609, 121137. [CrossRef]
38. 38. Bugatti, S., Manzo, A., Montecucco, C., et al. (2018). The clinical value of autoantibodies in rheumatoid arthritis. Frontiers in Medicine (Lausanne), 5, 339. [CrossRef]
39. 39. Erre, G.L., Mundula, N., Colombo, E., et al. (2019). Diagnostic accuracy of anticarbamylated protein antibodies in established rheumatoid arthritis: A monocentric cross-sectional study. American College of Rheumatology Open Rheumatology, 1(7), 433-439. [CrossRef]
40. 40. Verheul, M.K., Böhringer, S., van Delft, M.A.M., et al. (2018). Triple positivity for anti-citrullinated protein autoantibodies, rheumatoid factor, and anti-carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: Implications for very early identification of at-risk individuals. Arthritis & Rheumatology, 70(11), 1721-1731. [CrossRef]
41. 41. Scher, J.U., Abramson, S.B. (2011). The microbiome and rheumatoid arthritis. Nature Reviews Rheumatology, 7(10), 569-578. [CrossRef]
42. 42. Beyer, K., Zaura, E., Brandt, B.W., et al. (2018). Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health. PLoS One, 13(9), e0202278. [CrossRef]
43. 43. Kharlamova, N., Jiang, X., Sherina, N., et al. (2016). Antibodies to porphyromonas gingivalis indicate interaction between oral infection, smoking, and risk genes in rheumatoid arthritis etiology. Arthritis & Rheumatology, 68(3), 604-613. [CrossRef]
44. 44. Wang, W., Zhou, H., Liu, L. (2018). Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. European Journal of Medicinal Chemistry, 158, 502-516. [CrossRef]
45. 45. Torrecillas, R., Moya, J.S., Díaz, L.A., et al. (2009). Nanotechnology in joint replacement. WIREs: Nanomedicine and Nanobiotechnology, 1(5), 540-552. [CrossRef]
46. 46. Al-Jamal, A.N., Al-Hussainy, A.F., Mohammed, B.A., et al. (2025). Photodynamic Therapy (PDT) in drug delivery: Nano-innovations enhancing treatment outcomes. Health Sciences Review, 14, 100218. [CrossRef]
47. 47. Lu, Y., Li, L., Lin, Z., et al. (2018). A New Treatment Modality for Rheumatoid Arthritis: Combined Photothermal and Photodynamic Therapy Using Cu(7.2) S(4) Nanoparticles. Advanced Healthcare Materials, 7(14), e1800013. [CrossRef]
48. 48. Farokhzad, O.C., Langer, R. (2009). Impact of nanotechnology on drug delivery. American Chemical Society Nano, 3(1), 16-20. [CrossRef]
49. 49. Singh, R., Lillard, Jr.J.W. (2009). Nanoparticle-based targeted drug delivery. Experimental and Molecular Pathology, 86(3), 215-223. [CrossRef]
50. 50. Mitragotri, S., Yoo, J.W. (2011). Designing micro- and nano-particles for treating rheumatoid arthritis. Archives of Pharmacal Research, 34(11), 1887-1897. [CrossRef]
51. 51. Almalik, A., Benabdelkamel, H., Masood, A., et al. (2017). Hyaluronic acid coated chitosan nanoparticles reduced the immunogenicity of the formed protein corona. Scientific Reports, 7(1), 10542. [CrossRef]
52. 52. Nasra, S., Bhatia, D., Kumar, A. (2022). Recent advances in nanoparticle-based drug delivery systems for rheumatoid arthritis treatment. Nanoscale Advances, 4(17), 3479-3494. [CrossRef]
53. 53. Levick, J.R. (1981). Permeability of rheumatoid and normal human synovium to specific plasma proteins. Arthritis & Rheumatology, 24(12), 1550-1560. [CrossRef]
54. 54. Quiñonez-Flores, C.M., González-Chávez, S.A., Pacheco-Tena, C. (2016). Hypoxia and its implications in rheumatoid arthritis. Journal of Biomedical Science, 23, 62. [CrossRef]
55. 55. Nagayoshi, R., Nagai, T., Matsushita, K., et al. (2005). Effectiveness of anti-folate receptor beta antibody conjugated with truncated Pseudomonas exotoxin in the targeting of rheumatoid arthritis synovial macrophages. Arthritis & Rheumatology, 52(9), 2666-2675. [CrossRef]
56. 56. Kinne, R.W., Bräuer, R. Stuhlmüller, B., et al. (2000). Macrophages in rheumatoid arthritis. Arthritis Research & Therapy, 2(3), 189.
57. 57. Naor, D., Nedvetzki, S. (2003). CD44 in rheumatoid arthritis. Arthritis Research & Therapy, 5(3), 105-115.
58. 58. Harada, M., Mitsuyama, K., Yoshida, H., et al. (1998). Vascular endothelial growth factor in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 27(5), 377-380. [CrossRef]
59. 59. Ferrara, N. (1999). Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney International, 56(3), 794-814. [CrossRef]
60. 60. Ben-Av, P., Crofford, L.J., Wilder, R.L., et al. (1995). Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: A potential mechanism for inflammatory angiogenesis. Federation of European Biochemical Societies Letters, 372(1), 83-87. [CrossRef]
61. 61. Paleolog, E.M. (2009). The vasculature in rheumatoid arthritis: Cause or consequence? International Journal of Experimental Pathology, 90(3), 249-261. [CrossRef]
62. 62. Szekanecz, Z., Koch, A. (2009). Angiogenesis and its targeting in rheumatoid arthritis. Vascular Pharmacology, 51, 1-7. [CrossRef]
63. 63. Brooks, P.C., Clark, R.A., Cheresh, D.A. (1994). Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science, 264(5158), 569-571. [CrossRef]
64. 64. Wilder, R.L. (2002). Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Annals of the Rheumatic Diseases, 61(2), 96-99. [CrossRef]
65. 65. Storgard, M., Stupack, D.G., Jonczyk, A., et al. (1999). Decreased angiogenesis and arthritic disease in rabbits treated with an alpha v beta 3 antagonist. Journal of Clinical Investigation, 103(1), 47-54. [CrossRef]
66. 66. Gutiérrez-Cañas, I., Juarranz, Y., Santiago, B., et al. (2006). VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. Rheumatology (Oxford), 45(5), 527-532. [CrossRef]
67. 67. Delgado, M., Abad, C., Martinez, C., et al. (2001). Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nature Medicine, 7(5), 563-568. [CrossRef]
68. 68. Delgado, M., Abad, C., Martinez, C., et al. (2002) Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. Journal of Molecular Medicine (Berlin, Germany), 80(1), 16-24. [CrossRef]
69. 69. Kuuliala, A., Eberhardt, K., Takala, A., et al. (2002). Circulating soluble E-selectin in early rheumatoid arthritis: A prospective five year study. Annals of the Rheumatic Diseases, 61(3), 242-246. [CrossRef]
70. 70. Jubeli, E., Moine, L., Vergnaud-Gauduchon, J., et al. (2012). E-selectin as a target for drug delivery and molecular imaging. Journal of Controlled Release, 158(2), 194-206. [CrossRef]
71. 71. Wu, Y., Pan, W., Hu, X., et al. (2021). The prospects for targeting FcR as a novel therapeutic strategy in rheumatoid arthritis. Biochemical Pharmacology, 183, 114360. [CrossRef]
72. 72. Treuhaft, P.S., MCCarty, D.J. (1971). Synovial fluid pH, lactate, oxygen and carbon dioxide partial pressure in various joint diseases. Arthritis & Rheumatology, 14(4), 475-484. [CrossRef]
73. 73. Ng, C.T., Biniecka, M., Kennedy, A., et al. (2010). Synovial tissue hypoxia and inflammation in vivo. Annals of the Rheumatic Diseases, 69(7), 1389-1395. [CrossRef]
74. 74. Jing, W., Liu, C., Su, C., et al. (2023). Role of reactive oxygen species and mitochondrial damage in rheumatoid arthritis and targeted drugs. Frontiers in Immunology, 14, 1107670. [CrossRef]
75. 75. Bian, Y., Xiang, Z., Wang, Y., et al. (2023). Immunomodulatory roles of metalloproteinases in rheumatoid arthritis. Frontiers in Pharmacology, 14, 1285455. [CrossRef]
76. 76. Yang, J., des Rieux, A., Malfanti, A. (2025). Stimuli-responsive nanomedicines for the treatment of non-cancer related inflammatory diseases. American Chemical Society Nano, 19(16), 15189-15219. [CrossRef]
77. 77. Logesh, K., Raj, B., Bhaskaran, M., et al. (2023). Nanoparticulate drug delivery systems for the treatment of rheumatoid arthritis: A comprehensive review. Journal of Drug Delivery Science and Technology, 81, 104241. [CrossRef]
78. 78. Priya, S., Jain, K. K., Daryani, J., et al. (2025). Revolutionizing rheumatoid arthritis treatment with emerging cutaneous drug delivery systems: Overcoming the challenges and paving the way forward. Nanoscale, 17(1), 65-87. [CrossRef]
79. 79. Yang, L., Huang, H., Zeng, H., et al. (2023). Biomimetic chitosan nanoparticles with simultaneous water lubricant and anti-inflammatory. Carbohydrate Polymers, 304, 120503. [CrossRef]
80. 80. Trujillo-Nolasco, R.M., Morales-Avila, E., Ocampo-García, B.E., et al. (2019). Preparation and in vitro evaluation of radiolabeled HA-PLGA nanoparticles as novel MTX delivery system for local treatment of rheumatoid arthritis. Materials Science & Engineering C-Materials for Biological Applications, 103, 109766. [CrossRef]
81. 81. Zhao, M., Zhu, T., Chen, J., et al. (2021). PLGA/PCADK composite microspheres containing hyaluronic acid-chitosan siRNA nanoparticles: A rational design for rheumatoid arthritis therapy. International Journal of Pharmaceutics, 596, 120204. [CrossRef]
82. 82. Navarro, S.M., Morgan, T.W., Astete, C.E., et al. (2016). Biodistribution and toxicity of orally administered poly (lactic-co-glycolic) acid nanoparticles to F344 rats for 21 days. Nanomedicine, 11(13), 1653-1669. [CrossRef]
83. 83. Kataoka, K., Harada, A., Nagasaki, Y. (2001). Block copolymer micelles for drug delivery: Design, characterization and biological significance. Advanced Drug Delivery Reviews, 47(1), 113-131. [CrossRef]
84. 84. Deshmukh, A.S., Chauhan, P.N., Noolvi, M.N., et al. (2017). Polymeric micelles: Basic research to clinical practice. International Journal of Pharmaceutics, 532(1), 249-268. [CrossRef]
85. 85. Zhao, G., Zhang, H. (2018). Notch-1 siRNA and methotrexate towards a multifunctional approach in rhematoid arthritis management: A nanomedicine approach. Pharmaceutical Research, 35(6),123. [CrossRef]
86. 86. Smolen, J.S., Aletaha, D., Barton, A., et al. (2018). Rheumatoid arthritis. Nature Reviews Disease Primers, 4, 18001. [CrossRef]
87. 87. Wang, Q., Sun, X. (2017). Recent advances in nanomedicines for the treatment of rheumatoid arthritis. Biomaterials Science, 5(8), 1407-1420. [CrossRef]
88. 88. He, L., Qin, X., Fan, D., et al. (2021). Dual-stimuli responsive polymeric micelles for the effective treatment of rheumatoid arthritis. American Chemical Society Applied Materials & Interfaces, 13(18), 21076-21086. [CrossRef]
89. 89. Mora-Huertas, C.E., Fessi, H., Elaissari, A. (2010). Polymer-based nanocapsules for drug delivery. International Journal of Pharmaceutics, 385(1-2), 113-142. [CrossRef]
90. 90. Sukhorukov, G.B., Rogach, A.L., Garstka, M., et al. (2007). Multifunctionalized polymer microcapsules: Novel tools for biological and pharmacological applications. Small, 3(6), 944-955. [CrossRef]
91. 91. Bernardi, A., Zilberstein, A.C., Jäger, E., et al. (2009). Effects of indomethacin-loaded nanocapsules in experimental models of inflammation in rats. British Journal of Pharmacology, 158(4), 1104-1111. [CrossRef]
92. 92. Boechat, A.L., de Oliveira, C.P., Tarragô, A.M., et al. (2015). Methotrexate-loaded lipid-core nanocapsules are highly effective in the control of inflammation in synovial cells and a chronic arthritis model. International Journal of Nanomedicine, 10, 6603-6614. [CrossRef]
93. 93. Tomalia, D., Frechet, J. (2002). Discovery of dendrimers and dendritic polymers: A brief historical perspective. Journal of Polymer Science Part A: Polymer Chemistry, 40 (16), 2719-2728. [CrossRef]
94. 94. Menjoge, A.R., Kannan, R.M., Tomalia, D.A. (2010). Dendrimer-based drug and imaging conjugates: Design considerations for nanomedical applications. Drug Discovery Today, 15(5-6), 171-185. [CrossRef]
95. 95. Oliveira, I.M., Gonçalves, C., Oliveira, E.P., et al. (2021). PAMAM dendrimers functionalised with an anti-TNF α antibody and chondroitin sulphate for treatment of rheumatoid arthritis. Materials Science & Engineering C-Materials for Biological Applications, 121, 111845. [CrossRef]
96. 96. Hayder, M., Poupot, M., Baron, M., et al. (2011). A phosphorus-based dendrimer targets inflammation and osteoclastogenesis in experimental arthritis. Science Translational Medicine, 3(81), 81ra35. [CrossRef]
97. 97. Chuang, S.Y., Lin, C.H., Huang, T.H., et al. (2018). Lipid-based nanoparticles as a potential delivery approach in the treatment of rheumatoid arthritis. Nanomaterials (Basel), 8(1), 42. [CrossRef]
98. 98. Gregoriadis, G. (1995). Engineering liposomes for drug delivery: Progress and problems. Trends in Biotechnology, 13(12), 527-537. [CrossRef]
99. 99. Nkanga, C.I., Bapolisi, A., Okafor, N. I., et al. (2019). General perception of liposomes: Formation, manufacturing and applications. Ed: Catala, A. Liposomes - Advances and Perspectives. IntechOpen, New York, 1-24. [CrossRef]
100. 100. Van der Meel, R., Vehmeijer, L.J., Kok, R.J., et al. (2013). Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status. Advanced Drug Delivery Reviews, 65(10), 1284-1298. [CrossRef]
101. 101. Zheng, X., Yang, H., Zhang, Z., et al. (2024). pH-responsive size-adjustable liposomes induce apoptosis of fibroblasts and macrophages for rheumatoid arthritis treatment. Acta Biomaterialia, 179, 256-271. [CrossRef]
102. 102. Meka, R.R., Venkatesha, S.H., Acharya, B., et al. (2019). Peptide-targeted liposomal delivery of dexamethasone for arthritis therapy. Nanomedicine (Lond), 14(11), 1455-1469. [CrossRef]
103. 103. Geszke-Moritz, M., Moritz, M. (2016). Solid lipid nanoparticles as attractive drug vehicles: Composition, properties and therapeutic strategies. Materials Science & Engineering C-Materials for Biological Applications, 68, 982-994. [CrossRef]
104. 104. Mehnert, W., Mäder, K. (2001). Solid lipid nanoparticles: Production, characterization and applications. Advanced Drug Delivery Reviews, 47(2-3), 165-196. [CrossRef]
105. 105. Mirchandani, Y., Patravale, V.B., Brijesh, S. (2022). Hyaluronic acid-coated solid lipid nanoparticles enhance antirheumatic activity and reduce toxicity of methotrexate. Nanomedicine (Lond), 17(16), 1099-1114. [CrossRef]
106. 106. El-Refaie, W.M., Ghazy, M.S., Ateyya, F.A., et al. (2023). Rhein methotrexate-decorated solid lipid nanoparticles altering adjuvant arthritis progression through endoplasmic reticulum stress-mediated apoptosis. Inflammopharmacology, 31(6), 3127-3142. [CrossRef]
107. 107. Zhou, M., Hou, J., Zhong, Z., et al. (2018). Targeted delivery of hyaluronic acid-coated solid lipid nanoparticles for rheumatoid arthritis therapy. Drug Delivery, 25(1), 716-722. [CrossRef]
108. 108. Das, S., Chaudhury, A. (2011). Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. PharmSciTech, 12(1), 62-76. [CrossRef]
109. 109. Sharma, S., Ghosh, R., Marianesan, A.B., et al. (2025). Nanostructured lipid carriers in rheumatoid arthritis: Treatment, advancements and applications. Inflammopharmacology, 33, 941-958. [CrossRef]
110. 110. Gu, Y., Tang, X., Yang, M., et al. (2019). Transdermal drug delivery of triptolide-loaded nanostructured lipid carriers: Preparation, pharmacokinetic, and evaluation for rheumatoid arthritis. International Journal of Pharmaceutics, 554, 235-244. [CrossRef]
111. 111. Zewail, M., Nafee, N., Helmy, M.W., et al. (2019). Coated nanostructured lipid carriers targeting the joints - An effective and safe approach for the oral management of rheumatoid arthritis. International Journal of Pharmaceutics, 567, 118447. [CrossRef]
112. 112. Kazi, K.M., Mandal, A.S., Biswas, N. et al. (2010). Niosome: A future of targeted drug delivery systems. Journal of Advanced Pharmaceutical Technology & Research, 1(4), 374-380. [CrossRef]
113. 113. Abidin, L., Mujeeb, M., Imam, S.S., et al. (2016). Enhanced transdermal delivery of luteolin via non-ionic surfactant-based vesicle: Quality evaluation and anti-arthritic assessment. Drug Delivery, 23(3), 1079-1084. [CrossRef]
114. 114. Anchan, R., Ghadi, A., Chauhan, M.A., et al. (2025). Understanding the role of ethosomes in rheumatoid arthritis: Innovative solutions to challenges in transdermal delivery of synthetic drugs and phytoconstituents. Journal of Drug Targeting, 1-15. [CrossRef]
115. 115. Paliwal, S., Tilak, A., Sharma, J., et al. (2019). Flurbiprofen-loaded ethanolic liposome particles for biomedical applications. Journal of Microbiological Methods, 161, 18-27. [CrossRef]
116. 116. Kalluri, R., LeBleu, V.S. (2020). The biology, function, and biomedical applications of exosomes. Science, 367(6478), eaau6977. [CrossRef]
117. 117. Raposo, G., Stoorvogel, W. (2013). Extracellular vesicles: Exosomes, microvesicles, and friends. Journal of Cell Biology, 200(4), 373-383. [CrossRef]
118. 118. Wang, X., He, L., Huang, X., et al. (2021). Recent progress of exosomes in multiple myeloma: Pathogenesis, diagnosis, prognosis and therapeutic strategies. Cancers (Basel), 13(7), 1635. [CrossRef]
119. 119. Liu, C., Su, C. (2019). Design strategies and application progress of therapeutic exosomes. Theranostics, 9(4), 1015-1028. [CrossRef]
120. 120. Campanella, C., Caruso Bavisotto, C., Logozzi, M., et al. (2019). On the choice of the extracellular vesicles for therapeutic purposes. International Journal of Molecular Sciences, 20(2), 236. [CrossRef]
121. 121. Chen, Z., Wang, H., Xia, Y., et al. (2018). Therapeutic potential of mesenchymal cell-derived miRNA-150-5p-expressing exosomes in rheumatoid arthritis mediated by the modulation of MMP14 and VEGF. Journal of Immunology, 201(8), 2472-2482. [CrossRef]
122. 122. Heydari, R., Koohi, F., Rasouli, M., et al. (2023). Exosomes as rheumatoid arthritis diagnostic biomarkers and therapeutic agents. Vaccines (Basel), 11(3), 687. [CrossRef]
123. 123. Singh, Y., Meher, J.G., Raval, K., et al. (2017). Nanoemulsion: Concepts, development and applications in drug delivery. Journal of Controlled Release, 252, 28-49. [CrossRef]
124. 124. Gokhale, J.P., Mahajan, H.S., Surana, S.J. (2019). Quercetin loaded nanoemulsion-based gel for rheumatoid arthritis: In vivo and in vitro studies. Biomedicine & Pharmacotherapy, 112, 108622. [CrossRef]
125. 125. Poonia, N., Lather, V., Kaur, B., et al. (2020). Optimization and development of methotrexate- and resveratrol-loaded nanoemulsion formulation using box-behnken design for rheumatoid arthritis. Assay and Drug Development Technologies, 18(8), 356-368. [CrossRef]
126. 126. Elsayed, M., Norredin, A. (2019).The Potential Contribution of Nanoparticles in the Treatment of Inflammatory Diseases. Ed: Nunes, A.C.F. Translational Studies on Inflammation, IntechOpen, New York, 1-15. [CrossRef]
127. 127. Costa Lima S.A., Reis, S. (2015). Temperature-responsive polymeric nanospheres containing methotrexate and gold nanoparticles: A multi-drug system for theranostic in rheumatoid arthritis. Colloids and Surfaces B: Biointerfaces, 133, 378-387. [CrossRef]
128. 128. Wang, H., Zhou, Y., Sun, Q., et al. (2021). Update on nanoparticle-based drug delivery system for anti-inflammatory treatment. Frontiers in Bioengineering and Biotechnology, 9, 630352. [CrossRef]
129. 129. Le, N., Zhang, M., Kim, K. (2022). Quantum dots and their interaction with biological systems. International Journal of Molecular Sciences, 23(18), 10763. [CrossRef]
130. 130. Wagner, A.M., Knipe, J.M., Orive, G., et al. (2019). Quantum dots in biomedical applications. Acta Biomaterialia, 94, 44-63. [CrossRef]
131. 131. Lin, Y., Tang, Y., Yi, O., et al. (2024). Graphene oxide quantum dots-loaded sinomenine hydrochloride nanocomplexes for effective treatment of rheumatoid arthritis via inducing macrophage repolarization and arresting abnormal proliferation of fibroblast-like synoviocytes. Journal of Nanobiotechnology, 22(1), 383. [CrossRef]
132. 132. Ding, Q., Zhang, S., Liu, X., et al. (2023). Hydrogel tissue bioengineered scaffolds in bone repair: A review. Molecules, 28(20), 7039. [CrossRef]
133. 133. Soni, K.S., Desale, S.S., Bronich, T.K. (2016). Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation. Journal of Controlled Release, 240, 109-126. [CrossRef]
134. 134. Yeo, J., Lee, Y.M., Lee, J., et al. (2019). Nitric oxide-scavenging nanogel for treating rheumatoid arthritis. Nano Letters, 19(10), 6716-6724. [CrossRef]
135. 135. Argenziano, M., Dianzani, C., Ferrara, B., et al. (2017). Cyclodextrin-based nanohydrogels containing polyamidoamine units: A new dexamethasone delivery system for inflammatory diseases. Gels, 3(2), 22. [CrossRef]
136. 136. Sonigra, A., Nel, H.J., Wehr, P., et al. (2022). Randomized phase I trial of antigen-specific tolerizing immunotherapy with peptide/calcitriol liposomes in ACPA+ rheumatoid arthritis. Journal of Clinical Investigation Insight, 7(20), e160964. [CrossRef]
137. 137. Clinical Trials website. (2008). https://clinicaltrials.gov/study/NCT00241982?term=NCT00241982 &rank=1/. Erişim tarihi: 31.07.2025.
138. 138. Clinical Trials website. (2021). https://clinicaltrials.gov/search?term=NCT05117593/. Erişim tarihi: 31.07.2025.